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Background: Nucleolin, as a multifunctional protein, has been demonstrated to play an oncogenic role in human
hepatocellular carcinoma (HCC). The aim of this study was to investigate the expression pattern of nucleolin in HCC
and determine its correlation with tumor progression and prognosis.
Methods: Nucleolin expression at both mRNA and protein levels in HCC and adjacent nonneoplastic tissues were
respectively detected by quantitative real time polymerase chain reaction (Q-PCR), immunohistochemistry and
western blotting.
Results: Nucleolin expression, at both mRNA and protein levels, was significantly higher in HCC tissues than in the
adjacent nonneoplastic tissues (both P < 0.001). In addition, the elevated nucleolin expression was markedly
correlated with advanced tumor stage (P = 0.001), high tumor grade (P = 0.02) and serum AFP level (P = 0.008).
Moreover, HCC patients with high nucleolin expression had shorter 5-year disease-free survival and shorter 5-year
overall survival than those with low expression (both P < 0.001). Furthermore, the Cox proportional hazards model
showed that nucleolin expression was an independent poor prognostic factor for both 5-year disease-free survival
(hazards ratio [HR] = 3.696, 95% confidence interval [CI] = 1.662-8.138, P = 0.01) and 5-year overall survival (HR = 3.872,
CI = 1.681-8.392, P = 0.01) in HCC.
Conclusion: These results showed that the markedly and consistently increasing expression of nucleolin may be
associated with aggressive characteristics of HCC, and implied that nucleolin expression may serve as a promising
biochemical marker for predicting the clinical outcome of patients with this malignancy.
Virtual Slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/
vs/13000_2014_175.
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Hepatocellular carcinoma (HCC), accounts for approxi-
mately 90% of liver cancers, is the third cause of cancer
mortality worldwide, with 700,000 new cases annually
[1]. Nearly 85% cases with HCC occur in developing
countries of East Asia and sub-Saharan Africa [2]. In* Correspondence: lba302@163.com; ddwang304@163.com
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unless otherwise stated.China, HCC is the second leading cause of cancer-related
death among men. Its five-year postoperative survival rate
is only 30% to 40% [3]. As a highly aggressive solid tumor,
HCC is characterized by fast infiltrating growth, early me-
tastasis, high-grade malignancy, and poor prognosis. Cur-
rently, hepatic resection is the first choice for patients
suffering with HCC, however, the long-term survival re-
mains unsatisfactory mainly due to a high incidence of
postoperative metastasis and recurrence, and the high re-
sistance of HCC to chemotherapy [4]. Accumulating stud-
ies have demonstrated that the progression of HCC is a
complicate process which is associated with environmental. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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ease) and genetic/epigenetic alterations [5]. However, the
molecular mechanism of the tumor development and pro-
gression in HCC has not been fully elucidated. Thus, it is
extremely necessary to illustrate the mechanisms under-
lying hepatocarcinogenesis and the process of tumor inva-
sion and tumor metastasis, and further identify efficient
molecular markers for early diagnosis and prognosis as
well as valuable therapeutic targets.
Nucleolin is a multifunctional and mobile protein which
can shuttle among the nucleolus, nucleoplasm, cytoplasm,
and cytoplasmic membrane [6]. It is originally identified
by Orrick et al. [7] in 1973, and then, the same protein
was extracted from ovary cells of Chinese hamster,
and several other eukaryotic cells, including human, rat,
mouse, and chicken [8]. Nucleolin has an apparent mo-
lecular mass of 100–110 kDa as determined by SDS-PAGE
and a calculated molecular mass of 76–77 kDa as pre-
dicted by the amino acid sequence. This difference may be
due to posttranslational modifications and a high content
of negatively charged amino acids in the N-terminal part
of nucleolin [9]. Functionally, it is implicated in many as-
pects of DNA metabolism, and participates extensively
in RNA regulatory mechanisms, including transcription,
ribosome assembly, mRNA stability and translation, and
microRNA processing [10]. Nucleolin is also involved in
pathological processes, particularly cancer. It is overex-
pressed in highly proliferative cells, especially in several
malignant cells, including neuroblastoma, cutaneous mel-
anoma, pediatric intracranial ependymoma, breast cancer,
lung cancer, colon cancer [11-16]. Nucleolin functions as
a oncogene and regulates the abilities of cancer cells to
grow and proliferate, overcome senescence, evade apop-
tosis and the immune system, invade and metastasize
other tissues and promote angiogenesis. To our interests,
Bao et al. [17] identified nucleolin as a candidate bio-
marker for diagnosis of HCC by quantitative proteomic
analysis of a paired human liver healthy versus carcinoma
cell lines with the same genetic background; Meng et al.
[18] further found that the downregulation of nucleolin
expression may inhibit the growth of HCC cells in vitro.
These previous studies suggest that nucleolin plays a role
in HCC. However, its clinical significance remains unclear.
Therefore, the aim of the current study was to investigate
the expression pattern of nucleolin in HCC and determine
its correlation with tumor progression and prognosis.
Methods
Patients and tissue samples
The study was approved by the Research Ethics Commit-
tee of 302nd Hospital of PLA, Beijing, China. Informed
consent was obtained from all of the patients. All speci-
mens were handled and made anonymous according to
the ethical and legal standards.A total of 130 patients with primary HCC who under-
went a curative liver resection at the 302nd Hospital of
PLA, Beijing, China, were included in this retrospective
study. Tissues used in the study were retrieved from the
tissue bank of the Department of Pathology in the 302nd
Hospital of PLA. These patients were diagnosed as HCC
between March 2001 and February 2006. None of the pa-
tients recruited in this study had chemotherapy or radio-
therapy before the surgery. HCC diagnosis was based on
World Health Organization (WHO) criteria [19]. Tumor
differentiation was defined according to the Edmondson
grading system [20]. Liver function was assessed using the
Child-Pugh scoring system [21]. Tumor staging was deter-
mined according to the sixth edition of the tumor-node-
metastasis (TNM) classification of the International Union
against Cancer [22]. The clinicopathological features of
130 patients are summarized in Table 1. In addition, 30
matched HCC specimens (5 TNM stage I, 8 TNM stage
II, 12 TNM stage III, and 5 TNM stage IV) and adjacent
nonneoplastic liver tissues were collected between April
2008 and March 2010, snap-frozen in liquid nitrogen and
stored at −80°C following surgery for real-time quantita-
tive RT-PCR assay and western blot analysis.
The median follow-up period of 130 patients with primary
HCC was 8.6 years. Postoperative surveillance included rou-
tine clinical and laboratory examinations every third month,
computed tomography scans of the abdomen, and radio-
graphs of the chest every third month. After 5 years, the
examination interval was extended to 12 months.
Quantitative RT-PCR
To measure the mRNA expression levels of nucleolin,
total RNA was extracted from frozen liver tissues using
TriZol reagent (Invitrogen) following the manufacturer’s
instructions. Two micrograms of total RNA was subjected
to reverse transcription to synthesize cDNA using the
ProtoScript M-MuLV Taq RT-PCR Kit (New England Bio-
labs), according to the manufacture’s instruction, followed
by real-time PCR using the TransStart Green qPCR
SuperMix (TransGen Biotech). The primer sequences of
nucleolin were forward primer, 5′- GCA CTT GGA GTG
GTG AAT CAA A-3′, reverse primer, 5′- AAA TGC ATA
CCC TTT AGA TTT GCC-3′. The transcription of
GAPDH was used as an internal control for normalization.
nucleolin expression levels were calculated relative to
GAPDH using the delta-delta cycle threshold method [23].
Western blot
The Western blot protocol and semiquantitative analysis
were carried out following the protocol of Xu et al. [24].
nucleolin antibody (mouse monoclonal antibody, dilu-
tion 1:100, 4E2, #ab13541, Abcam Inc., Cambridge, UK)
was used, and GAPDH antibody (CW0266, dilution
1:1,000, CoWin Biotech) was used as internal control.
Table 1 Clinicopathological features and the expression







≤50 72 40 (55.56) 32 (44.44)
NS
>50 58 28 (48.28) 20 (51.72)
Gender
Male 96 58 (60.42) 42 (39.58)
NS
Female 34 20 (58.82) 14 (41.18)
Serum AFP
Positive 72 58 (80.56) 14 (19.44)
0.008
Negative 58 20 (34.48) 38 (65.52)
Tumor stage
T1 23 0 (0) 23 (100.00)
0.001
T2 40 23 (57.50) 17 (42.50)
T3 52 40 (76.92) 12 (23.08)
T4 15 15 (100.00) 0 (0)
Tumor grade
G1 31 12 (38.71) 19 (61.29)
0.02G2 76 48 (63.16) 28 (36.84)
G3 23 18 (78.26) 5 (21.74)
Growth pattern
Trabecular 101 59 (58.42) 42 (41.58)
NS
Nontrabecular 29 19 (65.52) 10 (34.48)
Cirrhosis
Yes 86 50 (58.14) 36 (41.86)
NS
No 44 28 (63.64) 16 (36.46)
Underlying liver disease
Alcoholic 25 10 (40.00) 15 (60.00)
NS
Hepatitis B 49 28 (57.14) 21 (42.86)
Hepatitis C 35 28 (80.00) 7 (20.00)
Unknown 21 12 (57.14) 9 (42.86)
Note: ‘NS’ refers to the differences among groups have no statistical significance.
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Immunohistochemical staining was carried out following
the protocol of our previous study [25-27]. The primary
antibody against nucleolin: mouse monoclonal antibody
(4E2, #ab13541, Abcam Inc., Cambridge, UK), dilution
1:100. Secondary antibody for the detection of primary
antibody: anti-goat IgG (#sc-2028, Santa Cruz Biotechnol-
ogy, Inc. USA). The negative controls were processed in a
similar manner with PBS instead of primary antibody. The
positive nucleolin expression confirmed by western blot-
ting was used as positive controls for immunostaining.
Following a hematoxylin counterstaining, immunostaining
was scored by two independent experienced pathologists,who were blinded to the clinicopathological parameters
and clinical outcomes of the patients. The scores of the
two pathologists were compared and any discrepant
scores were reconciled through re-examining the stainings
by both pathologists to achieve a consensus score. The
number of positive-staining cells showing immunoreactiv-
ity in the nucleus, cytoplasm and/or cytoplasmic mem-
brane for nucleolin in ten representative microscopic
fields was counted and the percentage of positive cells was
calculated. The percentage scoring of immunoreactive
tumor cells was as follows: 0 (0%), 1 (1-10%), 2 (11-50%)
and 3 (>50%). The staining intensity was visually scored
and stratified as follows: 0 (negative), 1 (weak), 2 (moder-
ate) and 3 (strong). A final score was obtained for each
case by multiplying the percentage and the intensity score.
Therefore, tumors with a multiplied score of less than
5.62 (median of total scores for nucleolin) were considered
to be low nucleolin expressers; all other scores were con-
sidered to be high nucleolin expressers.
Statistical analysis
The software of SPSS version13.0 for Windows (SPSS
Inc, IL, USA) and SAS 9.1 (SAS Institute, Cary, NC) was
used for statistical analysis. Fisher’s exact test [28] and
the X2 test [29] were performed to assess associations
between nucleolin expression and clinicopathological pa-
rameters. The Kaplan-Meier method [30] was used for
survival analysis, and differences in survival were esti-
mated using the log-rank test [31]. A multivariate sur-
vival analysis was performed for all parameters that were
significant in the univariate analyses using the Cox re-
gression model [32]. Differences were considered statis-
tically significant when P was less than 0.05.
Results
Increased expression of nucleolin mRNA and protein in HCC
Quantitative RT-PCR was performed to compare the ex-
pression level of nucleolin mRNA between 30 matched
tumor-normal specimens of HCC. We found that 22 of
30 patients (73.33%) had higher nucleolin mRNA ex-
pression in HCC tissues than in adjacent nonneoplastic
liver tissues. Statistical analysis showed that the relative
expression of nucleolin mRNA in HCC tissues was sig-
nificantly higher than in the adjacent nonneoplastic liver
tissues (2.61 ± 1.00 vs. 1.22 ± 0.76, P < 0.001; Figure 1A
and B). In addition, nucleolin expression at protein level
in HCC and adjacent nonneoplastic liver tissues were
also measured by Western blotting. Similar with the
quantitative RT-PCR results, the expression levels of
nucleolin protein in HCC tissues were markedly higher
than those in the adjacent nonneoplastic liver tissues
(3.17 ± 1.06 vs. 1.89 ± 0.79, P < 0.001; Figure 1C and D).
In order to confirm the subcellular localization of
nucleolin protein in HCC tissues, immunohistochemical
Figure 1 Nucleolin mRNA and protein expression in hepatocellular carcinoma (HCC) and adjacent nonneoplastic liver tissues.
(A) Representative graph of nucleolin mRNA levels in HCC tissues and adjacent nonneoplastic liver tissues (NL). (B) Quantitative RT-PCR assay
showed significantly decreased nucleolin mRNA level in HCC tissues compared with adjacent nonneoplastic liver tissues (P < 0.001). (C) Representative
Western blotting of nucleolin protein levels in HCC tissues and adjacent nonneoplastic liver tissues (NL). (D) Semiquantitative Western blotting showed
that the expression levels of nucleolin protein were significantly lower than those in adjacent nonneoplastic liver tissues (P < 0.001). GAPDH was used
as internal control. Means, standard deviation (SD), and P values were given (T test). (E), nucleolin positive staining was indicated by numerous yellowish
granules in the nucleus, cytoplasm and/or cytoplasmic membrane of HCC cells (Original magnification × 400). (F) Semiquantitative immunoreactive
scores showed that the expression levels of nucleolin protein were significantly lower than those in adjacent nonneoplastic liver tissues (P < 0.01).
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specimens of HCC. The immunostaining for nucleolin was
observed in the nucleus, cytoplasm and/or cytoplasmic
membrane of HCC cells (Figure 1E). The immunostaining
scores of nucleolin protein in HCC tissues were signifi-
cantly higher than those in adjacent nonneoplastic liver tis-
sues (5.19 ± 3.17 vs. 2.43 ± 1.34, P < 0.001; Figure 1F). In
130 HCC tissues, 78 (75/130, 60.00%) showed high nucleo-
lin expression, while 52 (40.00%, 52/130) displayed low
nucleolin expression.Association of nucleolin expression with the
clinicopathological features of HCC
To determine whether nucleolin protein expression levels
are indicative of the state of HCC progression, we ana-
lyzed the association between nucleolin immunostaining
scores and tumor stage, tumor grade, serum AFP level,
presence of cirrhosis, underlying liver disease including al-
cohol abuse, viral hepatitis B and C, gender, and age. As
summarized in Table 1, the statistically significant correla-
tions were observed between nucleolin expression and
Figure 2 Kaplan-Meier survival curves for nucleolin expression in hepatocellular carcinoma (HCC) patients. HCC patients with high nucleolin
expression had shorter 5-year disease-free survival (A) and shorter 5-year overall survival (B) than those with low expression (both P < 0.001).
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nucleolin expression more frequently occurred in HCC
tissues with advanced tumor stage (P = 0.001), high tumor
grade (P = 0.02) and high serum AFP level (P = 0.008) than
those with early tumor stage, low tumor grade and low
serum AFP level. In addition, nucleolin expression was not
statistically associated with patient age or gender, or several
of the classic markers for HCC progression, including the
presence of cirrhosis and underlying liver diseases.
Prognostic values of nucleolin expression in HCC
Five-year disease-free survival was observed in 30
(23.08%) patients, whereas in 100 (76.92%) patients, dis-
ease recurred, and 88 (67.69%) even died during a 5-year
follow-up period. We found a trend that 5-year disease-
free survival in the group with high nucleolin expression
was significantly shorter than that in the group with low
expression (P < 0.001, log-rank test; Figure 2A). Add-
itionally, the Kaplan-Meier plot of 5-year overall survival
curves stratified by nucleolin expression was shown in
Figure 2B. A significant relationship was also found be-





Serum AFP 1.931 0.685-4.056
Tumor stage 2.879 1.366-5.196
Tumor grade 1. 563 0.609-4.088
Presence of cirrhosis 1.919 0.738-4.102
nucleolin expression 3.872 1.681-8.392(P < 0.001, log-rank test, Figure 2B). Furthermore, the
Cox proportional hazards model showed that nucleolin
expression was an independent poor prognostic factor for
both 5-year disease-free survival (hazards ratio [HR] =
3.696, 95% confidence interval [CI] = 1.662-8.138, P = 0.01,
Table 2) and 5-year overall survival (HR = 3.872, CI =
1.681-8.392, P = 0.01, Table 2) in HCC.
Discussion
Early diagnosis of HCC, which is one of the most lethal
malignancies, is of great clinical significance and allows
the application of potentially curative treatments such as
surgical resection and liver transplantation, thus improv-
ing the prognosis in patients. In this regard, accumulat-
ing studies have performed to identify biomarkers for
the diagnosis and prognosis of HCC. Our current study
focus on the involvement of nucleolin, which promotes
cell proliferation and survival linked to carcinogenesis,
in HCC. We provide the first evidence that increased ex-
pression of nucleolin protein may be correlated with
poor prognosis of patients with HCC. Our data demon-
strated that nucleolin may be upregulated at bothdisease-free survival in 130 patients with hepatocellular
Five-year disease-free survival
P HR 95% CI P
0.063 1.953 0.615-4.273 0.062
0.009 2.686 1.386-6.009 0.01
0.081 1.551 0.607-4.466 0.086
0.063 1.921 0.793-4.219 0.062
0.01 3.696 1.662-8.138 0.01
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nonneoplastic liver tissues. Immunohistochemistry stain-
ing indicated that the high expression level of nucleolin
protein in histological sections was markedly correlated
with aggressive characteristics of human HCC includ-
ing advanced tumor stages, high tumor grade and posi-
tive serum AFP, and reduced disease-free survival and
overall survival of patients with HCC. We also identified
nucleolin as an independent prognostic marker for poor
clinical outcome.
As one of the most abundant nonribosomal proteins,
nucleolin is a RNA- and protein-binding protein exten-
sively expressed in exponentially growing eukaryotic
cells [7]. Functionally, it is implicated in the several as-
pects of transcription, cell proliferation and growth [8].
The subcellular localizations have been found to influ-
ence the functions of nucleolin. In the nucleolus, it con-
trols the process of DNA and RNA metabolisms; In the
cytoplasm, it shuttles proteins into the nucleus and pro-
vides a post-transcriptional regulation of strategic mRNAs;
And on the cell surface, it serves as an attachment protein
for several ligands involved in tumorigenesis and angio-
genesis [6]. Viewing this feature of nucleolin, we per-
formed the immunohistochemistry analysis to detect its
subcellular localizations in tumor cells and normal liver
cells. As a result, we found that the nuclear, cytoplasmic
and cytoplasmic membrane stainings of nucleolin were all
detected in HCC tissues while only nuclear staining was
found in nonneoplastic tissues, implying that the subcellu-
lar localization of nucleolin may change during the car-
cinogenesis of HCC. This change has been observed by
Qiu et al. in gastric cancer [12]. According to recent stud-
ies, nucleolin acts as an oncogene and enables normal
cells to become malignant through its RNA binding activ-
ity [33]. The synthesis of nucleolin is positively correlated
with increased rates of cell division. Thus, its expression
levels have been found to be elevated in tumors or other
rapidly dividing cells and are present at low levels in nor-
mal or quiescent cells [11-16], in line with which, the
Q-PCR and western blot analyses performed in the
current study both showed the higher expression of
nucleolin in HCC tissues than in adjacent non-neoplastic
liver tissues. More importantly, the aberrant expression of
nucleolin has also been demonstrated to be closely corre-
lated with tumor progression and prognosis in several
cancer types. For example, Qiu et al. [12] indicated that
the high expression level of nucleolin was an independent
prognostic marker for worse survival of patients with gas-
tric cancer; Zhao et al. [13] determined that nucleolin ex-
pression independently predicted for worse survival of
patients with non small cell lung cancer; Grinstein et al.
[14] identified nucleolin as activator of human papilloma-
virus type 18 oncogene transcription in cervical cancer;
High levels of nucleolin expression have also been shownto correlate with poor survival in patients with cuta-
neous melanoma and pediatric intracranial ependymoma
[15,16]. In contrast, Peng et al. [34] reported that high
levels of nucleolar expression of nucleolin may be associ-
ated with better prognosis in patients with stage II pancre-
atic ductal adenocarcinoma. Our study revealed that the
increased expression of nucleolin was dramatically associ-
ated with aggressive clinicopathological features of pa-
tients with HCC, such as advance tumor stage, high
tumor grade and high serum level of AFP. In the survival
analysis, a high level of nucleolin expression was associ-
ated with both shorter 5-year overall survival and 5-year
disease-free survival, and was an independent prognostic
factor in HCC patients.
Conclusion
In conclusion, these results showed that the markedly
and consistently increasing expression of nucleolin may
be associated with aggressive characteristics of HCC,
and implied that nucleolin expression may serve as a
promising biochemical marker for predicting the clinical
outcome of patients with this malignancy. Further stud-
ies are needed to investigate the precise function of
nucleolin in the progression of HCC.
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